<DOC>
	<DOCNO>NCT02684643</DOCNO>
	<brief_summary>This study design study compare efficacy cost-effectiveness individualized phosphate-lowering therapy comparison regular guideline-recommended therapy .</brief_summary>
	<brief_title>Study Individualized Therapy Hyperphosphatemia Maintenance Hemodialysis Patients</brief_title>
	<detailed_description>Hyperphosphatemia hemodialysis patient one difficult conundrum nephrologist past two decade . Elevated phosphate contributes secondary hyperparathyroidism , elevate FGF23 level , vascular calcification , turn predispose mortality population . Current guideline recommend limit dietary phosphate intake , strengthen dialysis use phosphate binder three therapy treatment hyperphosphatemia . Yet exact clinical implication remain ambiguous : intense restricted phosphate intake dosage phosphate binder dialysis adjust accordingly . Thus , treatment hyperphosphatemia effective enough , appear refractory . In current study , investigator design individualized phosphate-lowering therapy base patient 's phosphate-clearing ability , order observe compare efficacy cost-effectiveness individualized therapy regular guideline-recommended therapy .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>age 1870 year ' old dialysis vintage 3 month maintenance hemodialysis patient use internal arteriovenous fistula S [ P ] &gt; 1.45 mmol/l , PTH ( parathyroid hormone , PTH ) &lt; 900 ng/ml residual renal function ( RRF ) stable dietary habit clear consciousness capable communication willingness give write consent comply study protocol severe infection , anemia ( Hb &lt; 60 g/L ) , hypoproteinemia ( Alb &lt; 30 g/L ) pregnancy , lactate woman history severe coexisting disease , limit , chronic liver disease , myocardial infection , cerebrovascular accident , malignant hypertension history malignancy participation dietary , drugrelated , clinical trial within 1 month history complication relate elevated S [ P ] , limit primary hypoparathyroidism , type II vitamin D dependent rickets history noncompliance intolerance individualize therapy use calcitonin diphosphonate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>individualised therapy</keyword>
	<keyword>hyperphosphatemia</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>clinical trial</keyword>
	<keyword>restrict phosphate diet</keyword>
	<keyword>phosphate binder</keyword>
</DOC>